Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31492117 | 0.88 | CHRNA1 (0.35) | SLC6A4CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL21903898 | 0.88 | CHRNA1 (0.35) | SLC6A4CHRNA1CHRNGCHRNB1CHRNB2 | |
| Indoline SCHEMBL22344761 | 0.80 | KDM1A (0.34) | DRD2DRD3DRD4ALDH1A1KDM1A | |
| Indoline SCHEMBL23797119 | 0.80 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3 | |
| Indoline SCHEMBL22344747 | 0.79 | GAA (0.38) | ALDH1A1LMNATP53GAAHPGD | |
| Indoline SCHEMBL22344762 | 0.76 | DRD2 (0.47) | DRD2DRD3DRD4ALDH1A1KDM1A | |
| Indoline SCHEMBL28096138 | 0.72 | ALDH1A1 (0.49) | DRD2DRD4ALDH1A1LMNATP53 | |
| Indoline SCHEMBL9132798 | 0.72 | HTR2C (0.50) | DRD2DRD4ALDH1A1LMNATP53 | |
| Indoline SCHEMBL9400596 | 0.70 | DRD2 (0.46) | DRD2DRD3DRD4ALDH1A1LMNA | |
| Indoline SCHEMBL10798458 | 0.70 | ALDH1A1 (0.43) | DRD2DRD4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | SLC6A4 2283/4885SLC6A2 2075/4885SLC6A3 2287/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | SLC6A4 2283/4885SLC6A2 2075/4885SLC6A3 2287/4885 |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | ROCK1, ROCK2, RHOA | SLC6A4 4076/4885SLC6A2 3640/4885SLC6A3 3330/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | SLC6A4 2283/4885SLC6A2 2075/4885SLC6A3 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.